Trials / Completed
CompletedNCT04229836
Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
An International, Multicentre, Open- Label, Interventional Phase IV Clinical Study to Investigate the Efficacy and Safety of Tildrakizumab 100 mg in Patients With Moderate- Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 178 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of the study is to evaluate the efficacy, safety and impact on the health-related quality of life (HRQoL) in participants with moderate-to-severe chronic plaque psoriasis who are treated with tildrakizumab 100 milligrams (mg).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tildrakizumab 100 mg Solution for Injection | Participants will be treated with tildrakizumab 100 mg. |
Timeline
- Start date
- 2019-12-17
- Primary completion
- 2021-11-15
- Completion
- 2021-11-15
- First posted
- 2020-01-18
- Last updated
- 2023-03-03
Locations
39 sites across 2 countries: Italy, Spain
Source: ClinicalTrials.gov record NCT04229836. Inclusion in this directory is not an endorsement.